About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Dominik Paquet, Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
Brain research heavily depends on models recapitulating key aspects of human brain physiology and disease pathology. Human iPSCs have great potential to complement existing rodent disease models, as they allow directly studying affected human cell types. In addition, recent developments in CRISPR genome editing revolutionized how impacts of genetic alterations on disease formation can be investigated. Co-culture of disease-relevant iPSC-derived cells with disease-relevant mutations enables studying complex phenotypes involving cellular crosstalk. By combining iPSC-, CRISPR- and tissue engineering technologies, we established new brain tissue models for AD and FTD using iPSC-derived cortical neurons, astrocytes, and microglia, as well as a microfluidic model of the blood-brain-barrier (BBB) based on co-culture of endothelial cells, mural cells, and astrocytes. Our technology provides highly controllable and reproducible 3-dimensional tissues with typical cell morphologies and functional features. The brain tissue model displays widespread synapse formation, spontaneous and induced electrical activity, network formation, microglial ramification, tiling, and phagocytosis. It can be long-term cultured in a postmitotic state without proliferation or cell death, thus providing a more controllable, reproducible, and long-lived alternative to cortical organoids currently used for 3D disease modelling. Our fully iPSC-based BBB model forms barrier-containing and perfusable vessels with typical morphologies of all cell types, including formation of astrocytic end feet on the vessels. Register here to attend by Zoom: https://gencat.zoom.us/j/95402392896